CRMD stock forecast, quote, news & analysis

Key Takeaways

• CRMD has declined roughly 15.7% over the trailing 30 days, slipping from about $7.70 to a recent intraday level near $6.49.
• The pullback extends a broader slide tied to DefenCath's move off the transitional TDAPA add-on payment, which took effect July 1, 2026, and reduced net pricing in the second half of 2026.
• CorMedix has reaffirmed 2026 guidance of $325–345 million in revenue and $125–140 million in adjusted EBITDA, but its 2027 DefenCath outlook of $100–140 million assumes flat usage, pressuring sentiment.
• The stock is also lower over the trailing three months, falling approximately 13% amid reimbursement uncertainty and ongoing securities litigation.
• Near-term watch items include the Q3 2026 earnings report and the planned sNDA submission for REZZAYO in prophylaxis.
• For additional valuation and expectation data, explore CorMedix's Price Targets, Earnings, and Forecast pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.

CorMedix (CRMD) Company Overview and Market Position

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapies for the prevention and treatment of infectious and inflammatory diseases. Its lead product, DefenCath, is a catheter lock solution combining taurolidine and heparin. Approved by the FDA in late 2023, DefenCath is the first and only antimicrobial catheter lock solution in the United States indicated to reduce the risk of catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter.

The company broadened its commercial footprint in August 2025 with the roughly $300 million acquisition of Melinta Therapeutics, adding seven approved anti-infective products—including REZZAYO, MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL—to its hospital-focused portfolio. This transformation into a diversified specialty pharmaceutical company is central to why investors follow CRMD: DefenCath's market adoption, the integration of the Melinta assets, and late-stage pipeline opportunities such as REZZAYO in prophylaxis and DefenCath in total parenteral nutrition (TPN).

CorMedix (CRMD) Stock Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, CRMD has moved lower by approximately 15.7%, declining from a closing price near $7.70 to a recent intraday level around $6.49. The move has been uneven: shares initially weakened in early October before a mid-month recovery pushed prices back toward the $8.20 area, only to give back those gains in late October.

The longer view shows a similar pattern of pressure. Over the trailing three months, the stock has fallen roughly 13% from levels near $7.50 at the end of July. The shares had reached intraday highs above $8.90 in August before a steady erosion driven by reimbursement concerns. The net result is a stock trading well below the levels it held through the first half of 2026, with the most recent 30-day period accounting for the bulk of the decline.

What Drove CRMD Stock Price in the Last 30 Days

The dominant factor behind the recent move is the reimbursement transition for DefenCath. On July 1, 2026, DefenCath moved off the transitional drug add-on payment adjustment (TDAPA), which reduced net pricing and shifted revenue expectations toward the second half of the year. Investors have remained focused on whether utilization holds up as institutional reimbursement resets, creating sustained selling pressure in the shares.

Additional sentiment headwinds include the company's conservative 2027 outlook for DefenCath, which assumes flat usage among existing customers, and an ongoing securities class action lawsuit that remains in active discovery. Elevated short interest has also been cited as a factor amplifying volatility. Together, these concerns have outweighed the company's solid fundamentals, including a strong cash position and reaffirmed 2026 guidance, and contributed to the late-October leg lower ahead of the Q3 earnings report.

What Drove CRMD Stock Performance Over the Last Quarter

The quarterly decline reflects a broader repricing of CorMedix's growth narrative rather than a single event. Through 2025, DefenCath delivered rapid revenue growth under TDAPA, and the Melinta acquisition diversified the top line. The pivot point came when management outlined a more measured trajectory for 2026 and 2027, with lower-than-expected DefenCath revenue guidance tied to the reimbursement reset.

Against that backdrop, shares have struggled even as the company reported profitable quarters, raised adjusted EBITDA guidance, and secured supply agreements across the largest U.S. dialysis providers. The market's focus has shifted from near-term profitability to the durability of DefenCath demand after the reimbursement change and the timeline for pipeline catalysts such as REZZAYO's expanded indication. This reframing has kept the stock under pressure throughout the trailing three months.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader platform that operates hundreds of bots across thousands of tickers. Rather than listing every available strategy, the page surfaces only the top-performing and most relevant bots, giving traders a focused view of current momentum in the market. The bots vary by trading strategy, timeframe, and performance metrics, so the section serves as a practical starting point for comparing approaches rather than a single recommendation. Traders looking to monitor evolving market conditions can use the page to identify which AI strategies are gaining traction.

CRMD Stock Forecast Drivers: What Investors Should Watch Next

Several factors are likely to shape CRMD's near-term direction. The Q3 2026 earnings report will provide the clearest read on how DefenCath volumes and net pricing are holding up following the TDAPA step-down, and whether the company maintains its full-year revenue and adjusted EBITDA guidance. Investors will also watch for updates on Medicare Advantage contracting and new dialysis-operator utilization, both of which management has identified as potential levers for future DefenCath growth.

On the pipeline side, the planned sNDA submission for REZZAYO in prophylaxis and the continued enrollment in the DefenCath TPN Phase 3 study represent longer-term catalysts. Broader risks include competition in the heparin and anti-infective markets from larger players such as Pfizer and Amphastar Pharmaceuticals, as well as the outcome of ongoing litigation and any shifts in Medicare reimbursement policy. These developments will likely determine whether the recent decline stabilizes or extends.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations